Antiplatelet and Thrombolytic Drugs
Antiplatelet and Thrombolytic Drugs
Antiplatelet and Thrombolytic Drugs
Fibrinolytics
Antithrombotic drugs
Fibrinolytics
Antithrombotic drugs
Fibrinolytics
Antithrombotic drugs
Fibrinolytics
Peran Platelet
Peran Platelet
Peran Platelet
Peran Platelet
Obat-Obat Antiplatelet
Antiplatelet drugs
ADP antagonists
Beneficial in the treatment and prevention of ACS and the prevention of thromboembolic events
Dipyridamole
Secondary prevention in patients following stroke, often in combination with aspirin
GPIIb/IIIa antagonists
Administered intravenously, are effective during percutaneous coronary intervention (PCI)
Dipyridamole Farmakokinetik
Incompletely absorbed from the gastrointestinal
tract with peak plasma concentration occuring about 75 minutes after oral administration
More than 90% bound to plasma proteins A terminal half-life of 10 to 12 hours Metabolised in the liver Mainly excreted as glucuronides in the bile;
a small amount is excreted in the urine
Dipyridamole Penggunaan
Secondary prevention of ischaemic
complications after transient ischaemic attack (TIA) or ischaemic stroke (in combination with aspirin)
Dipyridamole Keterbatasan
Is not a very effective antithrombotic drug Dipyridamole also has a vasodilatory effect and
should be used with caution in patients with severe coronary artery disease; chest pain may be aggravated in patients with underlying coronary artery disease who are receiving dipyridamole